The identification of compounds with selective activity in CAFs - including FGFR inhibitors (erdafitinib, LY-2874455), the multikinase inhibitor midostaurin, the FAK inhibitor VS-4718, and less canonical agents such as the ferroptosis inducer RSL3 and the PDK1 inhibitor BX-912—underscores the potential of targeting the TME as a complementary strategy in PCa therapy (Supplementary Fig. 5B and Supplementary Table 4). Here, PDK1 is linked to posterior cortical atrophy.